Barclays reiterated coverage of Snap with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | Buy → Neutral | Guggenheim | |
| 2/5/2025 | Overweight | Barclays | |
| 2/5/2025 | $15.00 → $11.00 | Overweight → Equal Weight | Wells Fargo |
| 10/23/2024 | $17.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 9/20/2024 | $11.00 | Neutral | B. Riley Securities |
| 9/5/2024 | $8.00 | Neutral | Cantor Fitzgerald |
| 8/2/2024 | Buy → Hold | HSBC Securities | |
| 7/23/2024 | $12.00 → $16.00 | Underweight → Equal-Weight | Morgan Stanley |
Guggenheim downgraded Snap from Buy to Neutral
Barclays reiterated coverage of Snap with a rating of Overweight
Wells Fargo downgraded Snap from Overweight to Equal Weight and set a new price target of $11.00 from $15.00 previously
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). Pemgarda is
For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains